Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access                       
ValueForum.com Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain TBPH message board posts where the ticker symbol TBPH has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest TBPH SEC Filings

Filings Format Description Filing Date File/Film Number
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001179110-18-008316 Size: 6 KB
2018-06-08
CT ORDER  Documents Confidential treatment order
Acc-no: 9999999997-18-006163 (34 Act)  Size: 13 KB
2018-06-05 001-36033
18880264
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001179110-18-007440 Size: 5 KB
2018-05-23
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001179110-18-007377 Size: 4 KB
2018-05-22
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001179110-18-007376 Size: 4 KB
2018-05-22
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001179110-18-007375 Size: 4 KB
2018-05-22
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001179110-18-007374 Size: 4 KB
2018-05-22
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001179110-18-007373 Size: 4 KB
2018-05-22
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001179110-18-007372 Size: 4 KB
2018-05-22
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001179110-18-007371 Size: 4 KB
2018-05-22
More TBPH SEC Filings


Related news from
Thu, 12 Jul 2018
08:49:24 +0000
Edited Transcript of TBPH earnings conference call or presentation 9-May-17 9:00pm GMT
Q1 2017 Theravance Biopharma Inc Earnings Call
Tue, 03 Jul 2018
12:05:40 +0000
See what the IHS Markit Score report has to say about Theravance Biopharma Inc.
Theravance Biopharma Inc NASDAQ NMS:TBPH
Tue, 26 Jun 2018
14:50:30 +0000
When Can We Expect A Profit From Theravance Biopharma Inc (NASDAQ:TBPH)?
Theravance Biopharma Inc’s (NASDAQ:TBPH): Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics. The US$1.31b market-cap company’s loss lessens since it announced a -US$285.40m bottom-line inRead More...
Thu, 07 Jun 2018
15:56:03 +0000
Theravance Biopharma (TBPH) Down 1.9% Since Earnings Report: Can It Rebound?
Theravance Biopharma (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Wed, 06 Jun 2018
14:08:00 +0000
Antimicrobials Working Group Highlights Member Company Participation at ASM Microbe 2018
88 Presentations by Coalition Members During the Annual Meeting WASHINGTON , June 6, 2018 /PRNewswire/ -- The Antimicrobials Working Group (AWG) today announced that 13 of its member companies will present ...
Tue, 29 May 2018
20:20:00 +0000
Theravance Biopharma Highlights Submission of Regulatory Application in Japan for Once-Daily Single Inhaler Triple Therapy FF/UMEC/VI for Patients with COPD
DUBLIN, May 29, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma") today highlighted that a regulatory application for once-daily fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI 100/62.5/25 mcg) under the proposed brand name Trelegy Ellipta has been submitted to the Japanese Ministry of Health, Labour and Welfare (MHLW) for the treatment of adults with chronic obstructive pulmonary disease (COPD). Trelegy Ellipta is the triple combination therapy of FF/UMEC/VI in a single ELLIPTA® inhaler. Trelegy Ellipta is a product in which Theravance Biopharma has an economic interest in future payments that may be made by GlaxoSmithKline (GSK) or one of its affiliates pursuant to its agreements with Innoviva (formerly Theravance, Inc.).
Thu, 17 May 2018
12:30:00 +0000
Theravance Biopharma to Host Key Opinion Leader Event Focused on the Unmet Medical Need in the Treatment of Neurogenic Orthostatic Hypotension
DUBLIN, May 17, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) today announced that it will host a key opinion leader event focusing on neurogenic orthostatic hypotension (nOH) beginning at 12:00 p.m. ET on Thursday, May 24, 2018 in New York City. The event will feature a presentation by key opinion leader Roy Freeman, MB ChB, Harvard Medical School and the Beth Israel Deaconess Medical Center, who will discuss the current treatment landscape and unmet medical need in nOH.
Thu, 10 May 2018
16:02:22 +0000
High Growth Stocks To Profit From
Most investors find it challenging to find companies with prospective double-digit growth rates that are also financially robust. These hidden gems also add meaningful upside to a portfolio, should theRead More...
Thu, 10 May 2018
12:30:00 +0000
Theravance Biopharma to Present at the Bank of America Merrill Lynch 2018 Healthcare Conference
DUBLIN, May 10, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) announced today that Rick E Winningham, Chairman and Chief Executive Officer will participate in a fireside chat at the Bank of America Merrill Lynch 2018 Healthcare Conference on Thursday, May 17, 2018, at 10:40 a.m. PT. A live broadcast of each event will be available by visiting the Investor Relations section of Theravance Biopharma's website at www.theravance.com, under the Presentations & Events tab. Theravance Biopharma, Inc. ("Theravance Biopharma") is a diversified biopharmaceutical company with the core purpose of creating medicines that help improve the lives of patients suffering from serious illness.
Wed, 09 May 2018
15:03:03 +0000
Theravance Biopharma (TBPH) Q1 Loss Narrows, Sales Up Y/Y
Theravance Biopharma (TBPH) reports narrower-than-expected loss in Q1. Revenues surge year over year on increasing sales of Vibativ and collaborative revenues.
Tue, 08 May 2018
22:53:51 +0000
Theravance Bio: 1Q Earnings Snapshot
The George Town, Cayman Islands-based company said it had a loss of $1.22 per share. The results surpassed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...
Tue, 08 May 2018
20:05:00 +0000
Theravance Biopharma, Inc. Reports First Quarter 2018 Financial Results and Provides Business Update
Focusing on Advancement of Highest Priority Programs DUBLIN , May 8, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported ...
Tue, 01 May 2018
20:05:00 +0000
Theravance Biopharma to Report First Quarter 2018 Financial Results on May 8, 2018
DUBLIN, May 1, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma" or the "Company") today announced that it will release financial results for the period ended March 31, 2018 and provide a business update after market close on Tuesday, May 8, 2018. An accompanying conference call will be held at 5:00 pm ET on May 8, 2018.  To participate in the live call by telephone, please dial (855) 296-9648 from the US, or (920) 663-6266 for international callers, using the confirmation code 5379419. A replay of the conference call will be available on Theravance Biopharma's website for 30 days through June 7, 2018.
Wed, 25 Apr 2018
12:30:00 +0000
Theravance Biopharma Highlights Approval of Expanded Indication in the US for Once-Daily Trelegy Ellipta for Treatment of COPD Patients
DUBLIN, April 25, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma") today highlighted that the US Food and Drug Administration (FDA) has approved an expanded indication for Trelegy Ellipta. This expanded approval in the US allows Trelegy Ellipta to be used as a treatment for a broader population of chronic obstructive pulmonary disease (COPD) patients with airflow limitation or who have experienced an acute worsening of respiratory symptoms. Trelegy Ellipta is the triple combination therapy of fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in a single ELLIPTA® inhaler.
Mon, 23 Apr 2018
11:30:00 +0000
Theravance Biopharma Reports Positive New Data from Multiple Studies of VIBATIV® (telavancin) at 2018 ECCMID™ Conference
Data from TOUR™ Observational Patient Registry Demonstrate Clinical Response Rates with VIBATIV® (telavancin) Treatment Range from 76.5 - 78.8% for Obese and Elderly Patient Subgroups Additional Study ...
Fri, 20 Apr 2018
14:17:00 +0000
Antimicrobials Working Group Highlights Member Company Participation at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
71 Abstracts to be Presented by Coalition Members During the Annual Meeting WASHINGTON , April 20, 2018 /PRNewswire/ -- The Antimicrobials Working Group (AWG) today announced that thirteen of its member ...
Thu, 19 Apr 2018
20:05:00 +0000
Theravance Biopharma Highlights Landmark IMPACT Study Published in NEJM Showing Significant Benefits of Trelegy Ellipta for COPD Patients
DUBLIN, April 19, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma") today highlighted the publication in the New England Journal of Medicine (NEJM) of the landmark IMPACT study of Trelegy Ellipta in patients with chronic obstructive pulmonary disease (COPD). The IMPACT study is one of the largest trials ever conducted in COPD patients with a history of exacerbation.1 Trelegy Ellipta is the triple combination therapy of fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in a single ELLIPTA® inhaler.
Tue, 17 Apr 2018
12:30:00 +0000
Theravance Biopharma to Present New Data from Multiple Studies of VIBATIV® (telavancin) at 2018 ECCMID™ Conference
Data from TOUR™ Observational Patient Registry Highlights Positive Clinical Response Rates in Elderly and Obese Patients Additional VIBATIV Study Results Demonstrate Greater in vitro Potency than Competitor ...



"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "This is a site for sharing information about the atypical investments that the majority of investors have not discovered. It is about finding the next value/growth sector/investment before all the major houses on the Street are recommending it." more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
 
Nothing in ValueForum.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ValueForum.com. ©2003 - 2018, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards